<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01453478</url>
  </required_header>
  <id_info>
    <org_study_id>115550</org_study_id>
    <nct_id>NCT01453478</nct_id>
  </id_info>
  <brief_title>A Study to Look at How GSK1325756 is Taken up by the Body When Given by Mouth When Stomach Acid is Reduced</brief_title>
  <official_title>A Single Centre, 5-Period, Randomized Study To Evaluate The Relative Bioavailability Of An Immediate Release Tablet Formulation And Prototype Bioenhanced Formulations Of GSK1325756 In Healthy Elderly Subjects During Suppression Of Gastric Acid Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I study to assess the combined effects of food and suppression of gastric&#xD;
      acid secretion on the relative bioavailability of an immediate release (IR) tablet&#xD;
      formulation and prototype bioenhanced formulations of GSK1325756, an oral interleukin 8&#xD;
      receptor (IL8R also known as CXCR2) antagonist. The objectives are to understand if the&#xD;
      co-administration of food enhances absorption and the inter-subject variability for the&#xD;
      current GSK1325756 IR tablet under fed state proton pump inhibitor (PPI) conditions and&#xD;
      secondly to assess whether two proposed bioenhanced formulations offer any improvement over&#xD;
      the current GSK1325756 IR formulation under PPI conditions.&#xD;
&#xD;
      This open-label, randomized, 5-period crossover study will be completed in a single cohort of&#xD;
      subjects, with an interim analysis after completion of Treatment Period 4. During Treatment&#xD;
      Periods 1 to 4, subjects will be randomized to receive GSK1325756 50 mg IR in the fed state,&#xD;
      GSK1325756 50 mg IR in the fasted state, GSK1325756 Bioenhanced Formulation 1 in the fasted&#xD;
      state, and GSK1325756 Bioenhanced Formulation 2 in the fasted state. Progression to Treatment&#xD;
      Period 5 and the choice of bioenhanced formulation for dosing in this treatment period will&#xD;
      be dependent on the findings of an interim analysis of the pharmacokinetic profile and&#xD;
      relative bioavailability of each formulation following completion of Treatment Periods 1 to&#xD;
      4. In Treatment Period 5, subjects will receive the selected GSK1325756 bioenhanced&#xD;
      formulation in the fed state.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the relative bioavailability, including&#xD;
      the inter-subject variability, of the immediate release (IR) tablet used for the previous&#xD;
      Phase I studies and 2 prototype bioenhanced tablet formulations of GSK1325756 in healthy&#xD;
      elderly male and female subjects under fed and fasted states during suppression of gastric&#xD;
      acid secretion (concomitant omeprazole, 20 mg, once daily (QD)). Secondary objectives include&#xD;
      provision of information on the oral pharmacokinetic (PK) of GSK1325756 in the elderly under&#xD;
      different dosing conditions during suppression of gastric acid secretion, and additional&#xD;
      safety and tolerability information for oral administration of GSK1325756 in elderly&#xD;
      subjects.&#xD;
&#xD;
      The current study will provide an understanding of the PK of three formulations of GSK1325756&#xD;
      during gastric acid suppression in a population of 65 to 80 year old healthy adult subjects.&#xD;
      The effect of food on the PK of each GSK1325756 formulation will also be addressed in this&#xD;
      population. The outcome of this study is likely to guide selection of the most appropriate&#xD;
      formulation/dosing regimen for future studies.&#xD;
&#xD;
      The completed clinical studies demonstrated that to minimize inter-subject variability of the&#xD;
      exposure to GSK1325756, the current formulation needs to be administered with food,&#xD;
      particularly in elderly subjects. This does not preclude development of the current&#xD;
      formulation, but is not ideal, particularly if twice daily administration is needed in&#xD;
      chronic obstructive pulmonary disease (COPD) patients and for elderly subjects in which food&#xD;
      intake can be variable. In addition, the inter-subject variability in exposure with the&#xD;
      current formulation when given with omeprazole in the fasted state is not acceptable. This is&#xD;
      likely due to the need for a low pH (acid level) (pH &lt; 2) gastric environment, particularly&#xD;
      in the fasted state, to allow for sufficient solubilization of the GSK1325756 prior to&#xD;
      transport to the small intestine where it is absorbed. Thus, this study is being conducted&#xD;
      for the following reasons: (1) to determine if the current formulation results in acceptable&#xD;
      exposure and inter-subject variability if given with food in subjects in which gastric acid&#xD;
      secretion is suppressed with omeprazole and (2) to determine if a bio-enhanced formulation&#xD;
      can provide an acceptable exposure profile and acceptable inter-subject variability in the&#xD;
      fasted state in subjects in which gastric acid is suppressed. This information will be&#xD;
      important in helping to determine the appropriate formulation and dosing regimen for&#xD;
      progression to studies in COPD patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2011</start_date>
  <completion_date type="Actual">December 19, 2011</completion_date>
  <primary_completion_date type="Actual">December 19, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Forty eight hour period following dose</time_frame>
    <description>For determination of Area Under the blood concentration time Curve (AUC) for GSK1325756</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Forty eight hour period following dose</time_frame>
    <description>For determination of GSK1325756 pharmacokinetic parameters other than Area Under the blood concentration time Curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability information</measure>
    <time_frame>Study Duration</time_frame>
    <description>Adverse event (AE) reporting, vital signs, electrocardiograms (ECGs), changes in clinical laboratory parameters, and changes in clinical signs and symptoms from physical examination, as data permit.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>GSK1325756 Immediate Release 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered to volunteers in the fasted and fed states</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1325756 Bioenhanced Formulation 1 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered to volunteers in the fasted and/or fed states</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1325756 Bioenhanced Formulation 2 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered to volunteers in the fasted and/or fed states</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1325756</intervention_name>
    <description>CXCR2 antagonist</description>
    <arm_group_label>GSK1325756 Bioenhanced Formulation 1 50 mg</arm_group_label>
    <arm_group_label>GSK1325756 Bioenhanced Formulation 2 50 mg</arm_group_label>
    <arm_group_label>GSK1325756 Immediate Release 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-childbearing potential female who, at the time of signing the informed&#xD;
             consent, are aged between 65 and 80 years (inclusive). Non-childbearing potential is&#xD;
             defined as pre-menopausal females with a documented tubal ligation or hysterectomy or&#xD;
             postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases a&#xD;
             blood sample with simultaneous follicle stimulating hormone [FSH] greater than 40&#xD;
             milli-international units per milliliter MlU/mL) and estradiol less than 40 picograms&#xD;
             per milliliter (pg/mL) [less than 147 picomoles per liter (pmol/L)] is confirmatory).&#xD;
&#xD;
          -  Healthy, as determined by a responsible and experienced physician, based on a medical&#xD;
             evaluation including medical history, physical examination, laboratory tests and&#xD;
             cardiac monitoring. A subject with a clinical abnormality or laboratory parameters&#xD;
             outside the reference range for the population being studied may be included only if&#xD;
             the investigator and the GlaxoSmithKline (GSK) Medical Monitor agree that the finding&#xD;
             is unlikely to introduce risk factors and will not interfere with the study procedures&#xD;
             and objectives.&#xD;
&#xD;
          -  Aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase and&#xD;
             bilirubin less than or equal to 1.5 times the upper limit of normal (ULN) (isolated&#xD;
             bilirubin greater than 1.5 times the ULN is acceptable if bilirubin is fractionated&#xD;
             and direct bilirubin is less than 35 percent (%)).&#xD;
&#xD;
          -  Resting blood pressure of less than or equal to 160/95 millimeters of mercury (mm Hg),&#xD;
             irrespective of anti-hypertensive medication status for the subject.&#xD;
&#xD;
          -  Body weight greater than or equal to 60 kilograms (kg) for men and greater than or&#xD;
             equal to 45 kg for women; body mass index within the range 19 to 32 kiligrams per&#xD;
             meter squared (kg/m2) (inclusive).&#xD;
&#xD;
          -  Male subjects with female partners of child-bearing potential must agree to use two of&#xD;
             the following acceptable forms of contraception methods, one of which must be a&#xD;
             barrier method, from screening until 12 weeks after the last dose of study treatment:&#xD;
             1) Established use of oral, injected or implanted methods of contraception. (The&#xD;
             decision to allow use of hormonal contraceptives should be based on the&#xD;
             investigational medicinal product's metabolism and potential for interactions,&#xD;
             pharmacology and adverse event profile e.g., vomiting) 2) Placement of an intrauterine&#xD;
             device or system 3) Barrier method such as a condom or occlusive cap (diaphragm or&#xD;
             cervical/vault caps) with spermicidal foam/gel/film/cream/suppository. Barrier&#xD;
             contraceptives must always be supplemented with the use of a spermicide, which are not&#xD;
             a barrier method and therefore should not be used alone 4) Male sterilization 5) True&#xD;
             abstinence is acceptable when in line with the preferred and usual lifestyle of the&#xD;
             subject. If a subject is not usually sexually active but becomes active, they should,&#xD;
             with their partner, use two of the contraceptive methods listed above.&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen (HBsAg) or positive Hepatitis C&#xD;
             antibody (HCV Ab) result within 3 months of screening.&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen, with the exception of a positive result&#xD;
             considered by the investigator to be directly attributable to prescription medication&#xD;
             approved for subject use during the study.&#xD;
&#xD;
          -  A positive test for human immunodeficiency virus (HIV) antibody.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study defined as an&#xD;
             average weekly intake of greater than 21 units for males or greater than 14 units for&#xD;
             females. One unit is equivalent to 8 grams of alcohol: a half-pint (approximately 240&#xD;
             mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.&#xD;
&#xD;
          -  Positive urine beta-human chorionic gonadotropin (Î²-hCG) test at screening or prior to&#xD;
             first dose for female subjects.&#xD;
&#xD;
          -  Screening QT interval analysed by Bazett correction (QTcB) greater than 450 msec, PR&#xD;
             interval outside the range 120 to 220 msec or an ECG that is not suitable for QT&#xD;
             measurements (e.g., poorly defined termination of T wave).&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 3 months, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a&#xD;
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first&#xD;
             dose of study treatment until completion of the post-study medical, unless in the&#xD;
             opinion of the investigator and GlaxoSmithKline (GSK) Medical Monitor, the medication&#xD;
             will not interfere with the study procedures or compromise subject safety; examples&#xD;
             are anti-hypertensive medication for at least 3 months prior to the screening visit&#xD;
             and lipid-lowering medications (statins or fibrates) for at least 3 months prior to&#xD;
             the screening visit.&#xD;
&#xD;
          -  History of sensitivity to any of the study treatments, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or GSK&#xD;
             Medical Monitor, contraindicates their participation.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 milliliters (mL) within a 3-month period.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated.&#xD;
&#xD;
          -  Exhaled breath carbon monoxide levels indicative of smoking (greater than 10 parts per&#xD;
             million at screening), or history or regular use of tobacco- or nicotine-containing&#xD;
             products within 6 months prior to screening.&#xD;
&#xD;
          -  Consumption of red wine, Seville oranges, grapefruit or grapefruit juice and/or&#xD;
             pummelos, citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the&#xD;
             first dose of study treatment until collection of the final blood sample during each&#xD;
             treatment period.&#xD;
&#xD;
          -  Galactose intolerance, Lapp-lactase deficiency or glucose-galactose malabsorption.&#xD;
&#xD;
          -  Direct involvement in the conduct of the study, or relative of any person directly&#xD;
             involved in the conduct of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>October 13, 2011</study_first_submitted>
  <study_first_submitted_qc>October 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2011</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>115550</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115550</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115550</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115550</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115550</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115550</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115550</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

